Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Should You Buy?

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) shares gapped up before the market opened on Thursday . The stock had previously closed at $33.53, but opened at $34.74. Otsuka shares last traded at $34.64, with a volume of 9,942 shares.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on OTSKY shares. Morgan Stanley raised shares of Otsuka to an “overweight” rating in a research note on Friday, January 23rd. Zacks Research downgraded Otsuka from a “hold” rating to a “strong sell” rating in a research note on Monday, March 2nd. The Goldman Sachs Group lowered Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. Finally, UBS Group upgraded Otsuka to a “hold” rating in a report on Tuesday, January 27th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce”.

Otsuka Stock Performance

The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The stock has a market cap of $37.14 billion and a price-to-earnings ratio of 15.03. The stock’s fifty day moving average is $32.04 and its 200-day moving average is $29.42.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.